The oncogenic protein kinase Tpl-2/cot contributes to Epstein-Barr virus-encoded latent infection membrane protein 1-induced NF-KB signaling downstream of TRAF2

Journal of Virology

Volumn 76, Issue 9, 2002, Pages 4567-4579

  Eliopoulos, Aristides G ^a   Davies, Clare ^a   Blake, Sarah S M ^a   Murray, Paul ^a   Najafipour, Sohrab ^a   Tsichlis, Philip N ^a   Young, Lawrence S ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; CD40 ANTIGEN; CYCLOOXYGENASE 2; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LATENT MEMBRANE PROTEIN 1; PROTEIN KINASE; PROTEIN KINASE TPL 2; PROTEIN P105; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; UNCLASSIFIED DRUG;

ARTICLE; CARCINOGENESIS; CELL GROWTH; CELL SURVIVAL; CELL TRANSFORMATION; CONTROLLED STUDY; EMBRYO; EPSTEIN BARR VIRUS; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPRECIPITATION; NASOPHARYNX CARCINOMA; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION;

3T3 CELLS; ANIMALS; CARCINOMA; CARRIER PROTEINS; CELL LINE; CYCLOOXYGENASE 2; HERPESVIRUS 4, HUMAN; HODGKIN DISEASE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; ISOENZYMES; MAP KINASE KINASE KINASES; MEMBRANE PROTEINS; MICE; NASOPHARYNGEAL NEOPLASMS; NF-KAPPA B; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROTEINS; PROTO-ONCOGENE PROTEINS; RIBOSOMAL PROTEINS; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION; TNF RECEPTOR-ASSOCIATED FACTOR 2; TRANSFECTION;

EID: 0036223564     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.76.9.4567-4579.2002     Document Type: Article

References (61)

1. Tpl-2 kinase regulates the proteolysis of the NF-κB-inhibitory protein NF-κB1 p105
2. NF-κB inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cell lines
3. Epstein-Barr virus transformation: Involvement of latent membrane protein 1-mediated activation of NF-κB
4. Dbl and the Rho GTPases activate NF-κB by IκB kinase (IKK)-dependent and IKK-independent pathways J
5. Tpl-2 is an oncogenic kinase that is activated by carboxy-terminal truncation
6. Epstein-Burr virus latent membrane protein inhibits human epithelial cell differentiation
7. Cot kinase induces cyclooxygenase-2 expression in T cells through activation of the nuclear factor of activated T cells
8. TRAF1, TRAF2, and TRAF3 effect NF-KB activation by an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation
9. Role of the TRAF binding site and NF-KB activation in Epstein-Barr virus latent membrane protein 1-induced cell gene expression
10. TNF-alpha induction by LPS is regulated posttranscriptionally via a Tp12/ERK-dependent pathway
11. Epstein-Barr virus-encoded latent membrane protein 1 activates the JNK pathway via a mechanism involving TRADD and TRAF2
12. Activation of the p38 MAPK pathway by Epstein-Barr virus encoded latent membrane protein 1 (LMP1) co-regulates interleukin-6 and interleukin-8 production
13. Epstein-Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-κB pathway involving TNF receptor-associated factors
14. LMP1 structure and signal transduction
15. Involvement of the Tpl-2/cot oncogene in MMTV tumorigenesis
16. Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of A20 gene
17. Lineage-restricted function of nuclear factor κB-inducing kinase (N1K) in transducing signals via CD40
18. Cot proto-oncoprotein activates the dual specificity kinases MEK-1 and SEK-1 and induces differentiation of PC12 cells
19. Nuclear factor-kappa B activation is involved in LMPl-mediated transformation and tumorigenesis of Rat-1 fibroblasts
20. NF-κB p105 is a target of IκB kinases and controls signal induction of Bcl-3-p50 complexes
21. Induction of bcl-2 expression by the Epstein-Barr virus latent membrane protein-1 protects infected B cells from programmed cell death
22. The Epstein-Barr virus latent membrane protein 1 (LMPI) mediates activation of NF-κB and cell surface phenotype via two effector regions in its carboxyterminal cytoplasmic domain
23. Gastric carcinoma: Monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein
24. The Epstein-Barr virus oncoprotein latent membrane protein 1 engages the tumor necrosis factor receptor-associated proteins TRADD and receptor-interacting protein (RIP) but does not induce apoptosis or require RIP for NF-κB activation
25. How NF-κB is activated: The role of the IκB kinase (IKK) complex
26. Tumour necrosis factor receptor associated factor 2 is a mediator of NF-κB activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein
27. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation
28. Epstein-Barr virus and its replication
29. Transformation of Madin-Darby canine kidney (MDCK) epithelial cells by Epstein-Barr virus latent membrane protein 1 (LMP1) induces expression of Etsl and invasive growth
30. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders
31. Rac and Cdc42 induce actin polymerization and G1 cell cycle progression independently of p65PAK and the JNK/SAPK MAP kinase cascade
32. Cotranslational biogenesis of NF-κB p50 by the 26S proteasome
33. The proto-oncogene Cot kinase participates in CD3/CD28 induction of NF-κB acting through the NF-κB-inducing kinase and IκB kinases
34. Effects of the N1K aly mutation on NF-κB activation by the Epstein-Barr virus latent infection membrane protein, lymphotoxin beta receptor, and CD40
35. p105 and p98 precursor proteins play an active role in NF-κB-mediated signal transduction
36. Structure and transforming potential of the human Cot oncogene encoding a putative protein kinase
37. Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells
38. Identification of the cells expressing COT proto-oncogene messenger RNA
39. Tumor progression locus 2 (Tpl-2) encodes a protein kinase involved in the progression of rodent T-cell lymphomas and in T-cell activation
40. Tpl-2 acts in concert with Ras and Raf-1 to activate mitogen-activated protein kinase
41. Activation of the small GTPase Cdc42 by the inflammatory cytokines TNFα and IL-1, and by the Epstein-Barr virus transforming protein LMP1
42. Aberrant rel/nfkb genes and activity in human cancer
43. TRAF2-mediated activation of NF-κB by TNF receptor 2 and CD40
44. Monoclonal antibodies to the latent membrane protein of Epstein-Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells
45. Activation of MEK-1 and SEK-1 by Tpl-2 proto-oncoprotein, a novel MAP kinase kinase kinase
46. Activation of stress-activated protein kinase/cJun N-terminal kinase, but not NF-κB, by the tumor necrosis factor (TNF) receptor 1 through a TNF receptor-associated factor 2- and germinal center kinase related-dependent pathway
47. Over-expression of the Tpl-2/Cot oncogene in human breast cancer
48. Epstein-Barr virus-transforming protein latent membrane protein 1 activates transcription factor NF-‰B through a pathway that includes the NF-κB -inducing kinase and the 1κB kinases IKKα and 1KKr3
49. Critical roles of TRAF2 and TRAF5 in tumor necrosis factor-induced NF-κB activation and protection from cell death
50. Epstein-Barr virus and gastric carcinoma
51. A new rac target POSH is an SH3-containing scaffold protein involved in the JNK and NF-κB signalling pathways
52. N-ras genes are not mutated in Hodgkin and Reed-Sternberg cells: Results from single cell polymerase chain-reaction examinations
53. Tpl-2 induces IL-2 expression in T cell lines by triggering multiple signaling pathways that activate NFAT and NF-κB
54. Two differently regulated nuclear factor KB activation pathways triggered by the cytoplasmic tail of CD40
55. Transcriptional activation of the cyclooxygenase-2 gene in endotoxin-treated RAW 264.7 macrophages
56. Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: Deletion of the amino terminus abolishes activity
57. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells
58. NFκB and Sp1 elements are necessary for maximal transcription of toll-like receptor 2 induced by Mycobacterium avium
59. Regulation of NFκB1 proteins by the candidate oncoprotein BCL-3: Generation of NF-κB homodimers from the cytoplasmic pool of p50-p105 and nuclear translocation
60. LMP1 of Epstein-Barr virus, suppresses cellular senescence associated with the inhibition of pl6(1NK4a) p16(INK4a) expression
61. The expression of matrix metelloproteinase 9 is enhanced by Epstein-Bart Barr virus latent membrane protein I. 1